Autolus Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. It is focused on chimeric antigen receptor (CAR)-T cell therapy. Using a suite of proprietary and modular T cell programming technologies, it is engineering targeted, controlled and highly active T cell therapy product candidates that are designed to recognize target cells, break down their defense mechanisms and eliminate these cells. It has a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. Its products pipeline includes obe-cel (FELIX), obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting T Cell Receptor Beta Constant (TRBC) 1 and TRBC 2.

Employees

649

Sector

Pharmaceuticals

Calendar

03-09 - Q4 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
12/12/25	1.610 $	+1.26%	3,448,491
11/12/25	1.590 $	+3.92%	2,507,476
10/12/25	1.530 $	+2.68%	2,783,461
09/12/25	1.490 $	-6.29%	2,059,203
08/12/25	1.590 $	+2.58%	3,621,563

Delayed Quote Nasdaq, December 12, 2025 at 09:00 pm

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.610USD

Average target price

9.522USD

Spread / Average Target

+491.44%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 21:00:00 12/12/2025 GMT			5-day change	1st Jan Change
1.610 ^USD	+1.26%		+3.87%	-31.49%

12-12	European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading; Shares Still Up This Week	MT
12-09	European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading	MT

Capitalization	428M 365M 341M 321M 591M 38.81B 645M 3.98B 1.54B 18.29B 1.61B 1.57B 66.74B	P/E ratio 2025 *	-1.65x	P/E ratio 2026 *	-2.12x
Enterprise value	86.98M 74.1M 69.22M 65.12M 120M 7.88B 131M 808M 313M 3.71B 326M 319M 13.55B	EV / Sales 2025 *	1.16x	EV / Sales 2026 *	1.78x
Free-Float	3.32%	Yield 2025 *	-	Yield 2026 *	-

12-12	European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading; Shares Still Up This Week	MT
12-09	European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading	MT
12-08	Autolus Therapeutics plc Presents Initial Clinical Data in Pediatric R/R B-All Patients and Other Oncology Data At the American Society of Hematology Annual Meeting 2025	CI
12-08	European Equities Traded in the US as ADRs Little Changed in Monday Trading	MT
12-04	European Equities Traded in the US as American Depositary Receipts Flat in Thursday Trading	MT
12-03	European Equities Traded in the US as American Depositary Receipts Higher in Wednesday Trading	MT
12-01	European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading	MT
12-01	Autolus Therapeutics appoints Ryan Richardson to board of directors	RE
12-01	Autolus Therapeutics plc Appoints Ryan Richardson to Board of Directors	CI
11-26	European Equities Traded in the US as American Depositary Receipts Surge in Wednesday Trading	MT
11-25	European Equities Traded in the US as American Depositary Receipts Turn Sharply Higher in Tuesday Trading	MT
11-25	Autolus Therapeutics plc Announces National Institute for Health and Care Excellence Recommends Aucatzyl®? (Obecabtagene Autoleucel) as Treatment Option for Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-All)	CI
11-25	Autolus Says UK Health Body Recommended Aucatzyl as Treatment Option for Leukemia	MT

03-31	Truist Adjusts Price Target on Autolus Therapeutics to $10 From $11, Maintains Buy Rating	MT
11-18	Goldman Sachs Upgrades Autolus Therapeutics to Buy From Neutral, Adjusts Price Target to $7.60 From $7	MT
11-15	Redburn Atlantic Upgrades Autolus Therapeutics to Buy From Neutral, Price Target is $13	MT
18/03/24	Truist Securities Adjusts Price Target on Autolus Therapeutics to $10 From $9, Keeps Buy Rating	MT
12/02/24	Needham Adjusts Autolus Therapeutics Price Target to $9 From $8, Maintains Buy Rating	MT

Autolus Therapeutics plc Share Price

Equities

AUTL

US05280R1005

Pharmaceuticals

Valuation: Autolus Therapeutics plc

Chart: Autolus Therapeutics plc

Latest news: Autolus Therapeutics plc

Last Transcript: Autolus Therapeutics plc

Analysts' recommendations: Autolus Therapeutics plc

Press Releases: Autolus Therapeutics plc

News in other languages: Autolus Therapeutics plc

Quotes and Performance

Course Extremes

Managers and Directors: Autolus Therapeutics plc

Biopharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

12-08	Autolus Therapeutics Presents Updated Clinical Data from the CARLYSLE Trial in Patients with Severe Refractory Systemic Lupus Erythematosus at the American Society of Hematology (ASH) Annual Meeting 2025	GL
12-08	Autolus Therapeutics Presents Initial Clinical Data in Pediatric r/r B-ALL Patients and Other Oncology Data at the American Society of Hematology (ASH) Annual Meeting 2025	GL
12-01	Autolus Therapeutics Appoints Ryan Richardson to Board of Directors	GL
12-01	Autolus Therapeutics Appoints Ryan Richardson to Board of Directors	AQ
11-25	NICE Recommends AUCATZYL® (obecabtagene autoleucel) as a Treatment Option for Adult Patients (≥26 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)¹	GL

08/02/24	Biontech baut Kapazitäten durch Deal mit britischer Autolus aus
15/03/23	WDH: Morphosys besetzt Finanzressort neu
08/11/21	Wall Street : tendance hésitante avant de nouveaux indicateurs
08/11/21	Blackstone : investissement dans Autolus Therapeutics

1 day	+1.26%
1 week	+3.87%
Current month	+14.18%
1 month	+25.78%
3 months	+16.67%
6 months	-24.06%
Current year	-31.49%

1 week	1.46	1.68
1 month	1.2	1.68
Current year	1.1	2.8
1 year	1.1	2.8
3 years	1.1	7.45
5 years	1.1	9.98
10 years	1.1	53.24

Manager	Title	Age	Since
Martin Pulé CTO	Chief Tech/Sci/R&D Officer	52	31/08/2014
Christian Itin CEO	Chief Executive Officer	60	29/02/2016
Robert Dolski DFI	Director of Finance/CFO	55	06/08/2023

Director	Title	Age	Since
Christian Itin CHM	Chairman	60	30/09/2014
John Berriman BRD	Director/Board Member	77	31/07/2014
Cynthia Butitta BRD	Director/Board Member	70	28/02/2018

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
AUTOLUS THERAPEUTICS PLC	+1.26%	+3.87%	-35.34%	-7.47%	428M
REGENERON PHARMACEUTICALS, INC.	-0.74%	+3.19%	+1.37%	-0.84%	76.06B
CSL LIMITED	+2.86%	-0.09%	-33.73%	-38.08%	58.92B
SAMSUNG BIOLOGICS CO.,LTD.	+1.38%	+69.20%	+69.20%	+69.20%	53.01B
UCB	-2.24%	-4.93%	+30.25%	+221.80%	52.48B
BIOGEN INC.	+0.93%	-3.97%	+16.04%	-40.22%	25.54B
INNOVENT BIOLOGICS, INC.	+1.85%	-7.39%	+127.81%	+163.37%	18.76B
INCYTE CORPORATION	-0.72%	-6.94%	+39.18%	+15.08%	18.73B
ALTEOGEN INC.	-4.52%	-5.15%	+36.59%	+1,036.48%	15.67B
BRIDGEBIO PHARMA, INC.	+1.46%	+2.05%	+173.37%	+704.60%	14.48B
Average	+0.15%	-1.58%	+42.47%	+212.39%	33.41B
Weighted average by Cap.	+0.19%	-0.72%	+29.88%	+125.02%

	2025 *	2026 *
Net sales	75.06M 63.95M 59.73M 56.2M 103M 6.8B 113M 697M 270M 3.2B 282M 276M 11.69B	144M 122M 114M 107M 198M 13B 216M 1.33B 517M 6.13B 538M 527M 22.35B
Net income	-258M -220M -205M -193M -356M -23.38B -389M -2.4B -930M -11.02B -968M -948M -40.2B	-210M -179M -167M -157M -289M -18.98B -316M -1.95B -755M -8.95B -786M -770M -32.64B
Net Debt	-342M -291M -272M -256M -471M -30.93B -514M -3.17B -1.23B -14.58B -1.28B -1.25B -53.2B	-172M -147M -137M -129M -238M -15.62B -260M -1.6B -621M -7.36B -647M -633M -26.86B